Glaukos Co. (NYSE:GKOS) Stake Increased by Teacher Retirement System of Texas

Teacher Retirement System of Texas raised its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 606.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,247 shares of the medical instruments supplier's stock after buying an additional 17,382 shares during the quarter. Teacher Retirement System of Texas' holdings in Glaukos were worth $3,036,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of GKOS. Wellington Management Group LLP raised its position in shares of Glaukos by 294.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier's stock valued at $284,501,000 after acquiring an additional 1,630,270 shares in the last quarter. State Street Corp increased its stake in Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock valued at $254,626,000 after purchasing an additional 98,109 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Glaukos by 6.0% during the third quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier's stock worth $152,722,000 after purchasing an additional 66,134 shares during the period. William Blair Investment Management LLC bought a new position in shares of Glaukos in the 4th quarter worth about $121,390,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Glaukos by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 650,697 shares of the medical instruments supplier's stock valued at $97,566,000 after buying an additional 8,936 shares during the period. Institutional investors own 99.04% of the company's stock.

Remove Ads

Glaukos Price Performance

Shares of NYSE GKOS traded down $1.66 during mid-day trading on Friday, reaching $101.97. 676,518 shares of the company traded hands, compared to its average volume of 603,441. The firm has a market cap of $5.77 billion, a PE ratio of -35.53 and a beta of 0.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a fifty-two week low of $88.16 and a fifty-two week high of $163.71. The stock has a fifty day simple moving average of $130.52 and a 200-day simple moving average of $135.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Equities research analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on GKOS shares. Truist Financial raised their target price on shares of Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. UBS Group assumed coverage on Glaukos in a report on Friday, December 6th. They issued a "buy" rating and a $182.00 price target on the stock. Stephens raised Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. Citigroup upgraded Glaukos from a "neutral" rating to a "buy" rating and raised their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. Finally, Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $163.25.

Insider Buying and Selling at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.